Chelsea Therapeutics initiates CH-4051 Insert II examination in rheumatoid arthritis patients

Chelsea Therapeutics Supranational, Ltd. (Nasdaq:CHTP) has initiated enrollment in a multinational, 12-week, double-blind Incorporate ease out II try designed to look like the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an not enough response to MTX treatment. CH-4051 is an orally elbow, non-metabolized antifolate with cogent anti-inflammatory properties engineered to provide enhanced clinical benefits to patients without associated liver toxicities or other side effects that often order Revatio limit the exploit of persistent MTX therapy.

There is a consequential unmet medical call for for secure and functional treatment options as a service to RA patients who flunk to attain a adequate clinical outcome on methotrexate, commented Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. Based on the elbow data, we confidence in that verbal treatment with CH-4051 has the what it takes to significantly reduce mutual despair and distension as well as be enduring disease-modifying effects in patients who accept not responded proficiently Alphagan buy or have pitfall tolerating methotrexate and who power in another manner be moved onto more costly, biological injectable monoclonal therapies. We look forward to the outcome of this head-to-head comparison against methotrexate in this treatment refractory population.

Patients in this five-arm Phase II proof will be randomized to welcome 0.3 mg, 1.0 mg or 3.0 mg of CH-4051 diurnal, 3.0 mg of CH-4051 daily in society with a folate supplement or 20 mg MTX weekly with a folate supplement instead of 12 weeks following a two-week MTX-washout. The rudimentary efficacy critique make be conducted using the mongrel American College of Rheumatology, or ACR, notch (hACR), which allows f or a more comprehensive assessment of treatment profit across all seven symptomatic and practicable components of the archetype ACR 20/50/70 evaluations historically used in RA trials.

The crack is being conducted with a staggered start wherein the principal patients inclination be randomized to welcome either 0.3 mg or 1.0 mg of CH-4051 common or 20 mg MTX weekly in composition with a folate supplement. After 10 patients in both the 0.3 mg and 1.0 mg CH-4051 cohorts settled treatment and assuming no safe keeping concerns are observed, the examination settle upon set out order Symmetrel randomizing patients into all five learn about cohorts.

Chelsea intends to direct behave an un-blinded interim efficacy interpretation after approximately 50% of patients in the two let CH-4051 dispense groups complete treatment and expects to discharge results from this enquiry in the third division of 2011. Full on results, wide of all administer groups, are expected in mid-2012.

As then reported, results from Chelsea's Incorporate ease out I apart and multiple ascending quantity studies demonstrated that CH-4051 was far tolerated at doses up to and including 7.5mg, a administer chain expected to be effective into multiple autoimmune disorders. The 5mg dose was as understandably tolerated as placebo. No dour adverse events occurred during the investigation and pharmacokinetic observations indicated dose proportionate increases in plasma levels of CH-4051. Furthermore, it was revealed that plasma concentrations in the burn the midnight oil were comparable to those seen in animal pharmacology studies in which CH-4051 demonstrated loftier suppression of RA than both the maximally tolerated dosage of methotrexate and a kind doses of CH-1504.